Login to Your Account

LONDON – "Drugging the undruggable" is the bold claim newco Phoremost Ltd. is making for its technology. The Cambridge University spinout said it can systematically identify and access intracellular targets that are undruggable using classic approaches.

Partnering with patient advocacy organizations is an increasingly attractive avenue to speed drugs for rare indications into clinical development. 

Inmed Pharmaceuticals Ltd., a Canadian-listed start-up mixing cannabinoids and noncannabis elements for the treatment of glaucoma is working to move into the clinic this year and attract the kind of big pharma backers that have rallied to support cannabinoid drugmaker GW Pharmaceuticals plc.

More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: